Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8G4K

Complex of TbRII mini protein binder bound to the TbRII ECD

Summary for 8G4K
Entry DOI10.2210/pdb8g4k/pdb
Descriptor5HCS_TGFBR2_1, TGF-beta receptor type-2, SULFATE ION, ... (4 entities in total)
Functional Keywordstbrii, tgf-b type ii receptor, computationally designed mini protein binder, mpb, signaling protein
Biological sourcesynthetic construct
More
Total number of polymer chains2
Total formula weight24360.07
Authors
Schwartze, T.S.,Hinck, A.P. (deposition date: 2023-02-09, release date: 2024-08-14, Last modification date: 2025-09-03)
Primary citationYang, W.,Hicks, D.R.,Ghosh, A.,Schwartze, T.A.,Conventry, B.,Goreshnik, I.,Allen, A.,Halabiya, S.F.,Kim, C.J.,Hinck, C.S.,Lee, D.S.,Bera, A.K.,Li, Z.,Wang, Y.,Schlichthaerle, T.,Cao, L.,Huang, B.,Garrett, S.,Gerben, S.R.,Rettie, S.,Heine, P.,Murray, A.,Edman, N.,Carter, L.,Stewart, L.,Almo, S.C.,Hinck, A.P.,Baker, D.
Design of high-affinity binders to immune modulating receptors for cancer immunotherapy.
Nat Commun, 16:2001-2001, 2025
Cited by
PubMed Abstract: Immune receptors have emerged as critical therapeutic targets for cancer immunotherapy. Designed protein binders can have high affinity, modularity, and stability and hence could be attractive components of protein therapeutics directed against these receptors, but traditional Rosetta based protein binder methods using small globular scaffolds have difficulty achieving high affinity on convex targets. Here we describe the development of helical concave scaffolds tailored to the convex target sites typically involved in immune receptor interactions. We employed these scaffolds to design proteins that bind to TGFβRII, CTLA-4, and PD-L1, achieving low nanomolar to picomolar affinities and potent biological activity following experimental optimization. Co-crystal structures of the TGFβRII and CTLA-4 binders in complex with their respective receptors closely match the design models. These designs should have considerable utility for downstream therapeutic applications.
PubMed: 40011465
DOI: 10.1038/s41467-025-57192-z
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.24 Å)
Structure validation

249697

PDB entries from 2026-02-25

PDB statisticsPDBj update infoContact PDBjnumon